IDXX
IDEXX LABORATORIES INC /DE
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$696.86
+3.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.7B | 4.3B | 3.9B | 3.7B | 3.4B |
| Cost of Revenue | 1.7B | 1.6B | 1.5B | 1.5B | 1.4B |
| Gross Profit | 2.9B | 2.7B | 2.4B | 2.2B | 2.0B |
| Operating Expenses | |||||
| R&D Expense | 266.9M | 251.2M | 219.8M | 191.0M | 254.8M |
| SG&A Expense | 1.2B | 1.0B | 1.0B | 901.9M | 850.8M |
| General & Admin Expense | 467.8M | 404.8M | 442.3M | 335.8M | 326.2M |
| Selling & Marketing Expense | 683.4M | 643.5M | 588.5M | 566.1M | 524.5M |
| Other Expenses | — | — | — | — | 2.2M |
| Total Operating Expenses | 1.4B | 1.3B | 1.3B | 1.1B | 1.1B |
| Cost and Expenses | 3.2B | 2.9B | 2.8B | 2.6B | 2.5B |
| Operating Income (EBIT) | 1.5B | 1.4B | 1.1B | 1.1B | 898.8M |
| Non-Operating | |||||
| Interest Income | 2.8M | 2.4M | 12.7M | 5.6M | 1.1M |
| Interest Expense | 35.9M | 38.3M | 31.2M | 41.6M | 39.9M |
| Net Interest Income | (33.1M) | (35.8M) | (18.5M) | (36.0M) | (38.8M) |
| Other Non-Op Income/Expense | (27.1M) | (35.8M) | (18.5M) | (36.0M) | (38.8M) |
| Non-Operating Income (excl Interest) | (8.8M) | (2.4M) | (12.7M) | (5.6M) | (1.1M) |
| EBT (Pre-Tax Income) | 1.5B | 1.3B | 1.1B | 1.1B | 860.0M |
| Income Tax Expense | 296.8M | 264.7M | 222.0M | 216.1M | 180.9M |
| Bottom Line | |||||
| Net Income | 1.2B | 1.1B | 887.9M | 845.0M | 679.1M |
| Earnings from Cont. Ops | 1.2B | 1.1B | 887.9M | 845.0M | 679.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.2B | 1.1B | 887.9M | 845.0M | 679.1M |
| Per Share | |||||
| Basic EPS | $14.83 | $13.17 | $10.77 | $10.17 | $8.12 |
| Diluted EPS | $14.73 | $13.08 | $10.67 | $10.06 | $8.03 |
| Revenue Per Share | $59.15 | $53.73 | $47.26 | $44.07 | $40.27 |
| Shares | |||||
| Basic Shares Outstanding | 78.8M | 80.1M | 82.5M | 83.1M | 83.6M |
| Diluted Shares Outstanding | 79.0M | 80.7M | 83.2M | 84.0M | 84.6M |
| Profitability Metrics | |||||
| EBITDA | 1.7B | 1.5B | 1.3B | 1.2B | 1.0B |
| D&A | 158.0M | 145.2M | 129.9M | 114.9M | 111.9M |
| EBIT | 1.5B | 1.4B | 1.1B | 1.1B | 899.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026